Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis Available to Purchase

2.

Gertz

MA

,

Dispenzieri

A

.

Systemic amyloidosis recognition, prognosis, and therapy: a systematic review

.

JAMA

.

2020

;

324

(

1

):

79

-

89

.

3.

Varga

C

,

Dorbala

S

,

Lousada

I

, et al.

The diagnostic challenges of cardiac amyloidosis: a practical approach to the two main types

.

Blood Rev

.

2021

;

45

:

100720

.

4.

Vrana

JA

,

Gamez

JD

,

Madden

BJ

,

Theis

JD

,

Bergen

HR

,

Dogan

A

.

Classification of amyloidosis by laser microdissection and mass spectrometry–based proteomic analysis in clinical biopsy specimens

.

Blood

.

2009

;

114

(

24

):

4957

-

4959

.

5.

Dasari

S

,

Theis

JD

,

Vrana

JA

, et al.

Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples

.

Mayo Clin Proc

.

2020

;

95

(

9

):

1852

-

1864

.

6.

Mollee

P

,

Boros

S

,

Loo

D

, et al.

Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry

.

Clin Proteomics

.

2016

;

13

:

30

.

7.

Rezk

T

,

Gilbertson

JA

,

Mangione

PP

, et al.

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis

.

J Pathol Clin Res

.

2019

;

5

(

3

):

145

-

153

.

8.

Wisniowski

B

,

Wechalekar

A

.

Confirming the diagnosis of amyloidosis

.

Acta Haematol

.

2020

;

143

(

4

):

312

-

321

.

9.

Dorbala

S

,

Ando

Y

,

Bokhari

S

, et al.

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging

.

J Nucl Cardiol

.

2019

;

26

(

6

):

2065

-

2123

.

10.

Saïle

R

,

Deveaux

M

,

Hachulla

E

,

Descamps

J

,

Duquesnoy

B

,

Marchandise

X

.

Iodine-123-labelled serum amyloid P component scintigraphy in amyloidosis

.

Eur J Nucl Med

.

1993

;

20

(

2

):

130

-

137

.

11.

Hawkins

PN

,

Lavender

JP

,

Pepys

MB

.

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component

.

N Engl J Med

.

1990

;

323

(

8

):

508

-

513

.

12.

Hazenberg

BP

,

van Rijswijk

MH

,

Piers

DA

, et al.

Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis

.

Am J Med

.

2006

;

119

(

4

):

355.e15

-

355.e24

.

13.

Hawkins

PN

.

Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis

.

Curr Opin Nephrol Hypertens

.

2002

;

11

(

6

):

649

-

655

.

14.

Noordzij

W

,

Glaudemans

AWJM

,

Slart

RHJA

,

Dierckx

RA

,

Hazenberg

BPC

.

Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis

.

Amyloid

.

2012

;

19

(

4

):

208

-

211

.

15.

Bokhari

S

,

Castaño

A

,

Pozniakoff

T

,

Deslisle

S

,

Latif

F

,

Maurer

MS

.

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses

.

Circ Cardiovasc Imaging

.

2013

;

6

(

2

):

195

-

201

.

16.

Giblin

GT

,

Cuddy

SAM

.

Multimodality imaging in cardiac amyloidosis

.

Curr Cardiol Rep

.

2021

;

23

(

10

):

134

.

17.

Gillmore

JD

,

Maurer

MS

,

Falk

RH

, et al.

Nonbiopsy diagnosis of cardiac transthyretin amyloidosis

.

Circulation

.

2016

;

133

(

24

):

2404

-

2412

.

18.

Perugini

E

,

Guidalotti

PL

,

Salvi

F

, et al.

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy

.

J Am Coll Cardiol

.

2005

;

46

(

6

):

1076

-

1084

.

19.

Rapezzi

C

,

Quarta

CC

,

Guidalotti

PL

, et al.

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

.

JACC Cardiovasc Imaging

.

2011

;

4

(

6

):

659

-

670

.

20.

Glaudemans

AW

,

van Rheenen

RW

,

van den Berg

MP

, et al.

Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis

.

Amyloid

.

2014

;

21

(

1

):

35

-

44

.

21.

Hutt

DF

,

Quigley

AM

,

Page

J

, et al.

Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis

.

Eur Heart J Cardiovasc Imaging

.

2014

;

15

(

11

):

1289

-

1298

.

22.

Cohen

OC

,

Wechalekar

AD

.

Systemic amyloidosis: moving into the spotlight

.

Leukemia

.

2020

;

34

(

5

):

1215

-

1228

.

23.

Quarta

CC

,

Zheng

J

,

Hutt

D

, et al.

99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis

.

Eur Heart J Cardiovasc Imaging

.

2021

;

22

(

11

):

1304

-

1311

.

24.

Clerc

OF

,

Cuddy

SAM

,

Robertson

M

, et al.

Cardiac amyloid quantification using ¹²⁴I-evuzamitide (¹²⁴I-P5+14) versus ¹⁸F-florbetapir: a pilot PET/CT study

.

JACC Cardiovasc Imaging

.

2023

;

16

(

11

):

1419

-

1432

.

25.

Ruberg

FL

,

Grogan

M

,

Hanna

M

,

Kelly

JW

,

Maurer

MS

.

Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review

.

J Am Coll Cardiol

.

2019

;

73

(

22

):

2872

-

2891

.

26.

Phull

P

,

Sanchorawala

V

,

Connors

LH

, et al.

Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)

.

Amyloid

.

2018

;

25

(

1

):

62

-

67

.

27.

Moore

PT

,

Burrage

MK

,

Mackenzie

E

,

Law

WP

,

Korczyk

D

,

Mollee

P

.

The utility of ^99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience

.

Heart Lung Circ

.

2017

;

26

(

11

):

1183

-

1190

.

28.

Dorbala

S

.

Expanding indications for non-biopsy diagnosis of transthyretin amyloid cardiomyopathy

.

Eur Heart J

.

2023

;

44

(

24

):

2199

-

2201

.

29.

Poterucha

TJ

,

Elias

P

,

Bokhari

S

, et al.

Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution

.

JACC Cardiovasc Imaging

.

Jun 2021

;

14

(

6

):

1221

-

1231

.

30.

Marshall

G

,

Tate

J

,

Mollee

P

.

Borderline high serum free light chain kappa/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states

.

Am J Clin Pathol

.

2009

;

132

(

2

):

309

.

31.

Kennard

A

,

Hawley

C

,

Tate

J

, et al.

Comparison of Freelite and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis

.

Clin Chem Lab Med

.

2016

;

54

(

6

):

1045

-

1052

.

32.

Long

TE

,

Indridason

OS

,

Palsson

R

, et al.

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study

.

Blood Cancer J

.

2022

;

12

(

9

):

133

.

33.

Einarsson Long

T

,

Rögnvaldsson

S

,

Thorsteinsdottir

S

, et al.

Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the Istopmm study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

535

.

34.

Martinez-Naharro

A

,

Patel

R

,

Kotecha

T

, et al.

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment

.

Eur Heart J

.

2022

;

43

(

45

):

4722

-

4735

.

35.

Cuscaden

C

,

Ramsay

SC

,

Prasad

S

,

Goodwin

B

,

Smith

J

.

Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation

.

J Nucl Cardiol

.

2021

;

28

(

6

):

2845

-

2856

.

36.

González-López

E

,

Gallego-Delgado

M

,

Guzzo-Merello

G

, et al.

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction

.

Eur Heart J

.

2015

;

36

(

38

):

2585

-

2594

.

37.

AbouEzzeddine

OF

,

Davies

DR

,

Scott

CG

, et al.

Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction

.

JAMA Cardiol

.

2021

;

6

(

11

):

1267

-

1274

.

38.

Nitsche

C

,

Scully

PR

,

Patel

KP

, et al.

Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis

.

J Am Coll Cardiol

.

2021

;

77

(

2

):

128

-

139

.

39.

Masri

A

,

Chen

Y

,

Colavecchia

AC

, et al.

Coexisting calcific aortic stenosis and transthyretin cardiac amyloidosis: real-world evaluation of clinical characteristics and outcomes

.

J Am Heart Assoc

.

2025

;

14

(

2

):

e033251

.

40.

Hutt

DF

,

Fontana

M

,

Burniston

M

, et al.

Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid

.

Eur Heart J Cardiovasc Imaging

.

2017

;

18

(

12

):

1344

-

1350

.

41.

Shetty

M

,

Malhotra

S

.

Novel tracers for the imaging of cardiac amyloidosis

.

J Nucl Med Technol

.

2023

;

51

(

2

):

120

-

124

.

42.

Lee

SP

,

Lee

ES

,

Choi

H

, et al.

11C-Pittsburgh B PET imaging in cardiac amyloidosis

.

JACC Cardiovasc Imaging

.

2015

;

8

(

1

):

50

-

59

.

43.

Klunk

WE

,

Engler

H

,

Nordberg

A

, et al.

Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B

.

Ann Neurol

.

2004

;

55

(

3

):

306

-

319

.

44.

Yeo

JM

,

Waddell

B

,

Khan

Z

,

Pal

S

.

A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease

.

Alzheimers Dement (Amst)

.

2015

;

1

(

1

):

5

-

13

.

45.

Lee

SP

,

Suh

HY

,

Park

S

, et al.

Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis

.

J Am Coll Cardiol

.

2020

;

75

(

4

):

380

-

390

.

46.

Antoni

G

,

Lubberink

M

,

Estrada

S

, et al.

In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET

.

J Nucl Med

.

2013

;

54

(

2

):

213

-

220

.

47.

Sperry

BW

,

Bock

A

,

DiFilippo

FP

,

Donnelly

JP

,

Hanna

M

,

Jaber

WA

.

Cardiac pilot study of F18-florbetapir in the early evaluation of amyloidosis

.

Front Cardiovasc Med

.

2021

;

8

:

693194

.

48.

Law

WP

,

Wang

WY

,

Moore

PT

,

Mollee

PN

,

Ng

AC

.

Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study

.

J Nucl Med

.

2016

;

57

(

11

):

1733

-

1739

.

49.

Kircher

M

,

Ihne

S

,

Brumberg

J

, et al.

Detection of cardiac amyloidosis with ¹⁸F-florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy

.

Eur J Nucl Med Mol Imaging

.

2019

;

46

(

7

):

1407

-

1416

.

50.

Rosengren

S

,

Skibsted Clemmensen

T

,

Tolbod

L

, et al.

Diagnostic accuracy of [¹¹C]PIB positron emission tomography for detection of cardiac amyloidosis

.

JACC Cardiovasc Imaging

.

2020

;

13

(

6

):

1337

-

1347

.

51.

Oguchi

K

,

Katoh

N

,

Mochizuki

Y

, et al.

Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging

.

Amyloid

.

2023

;

30

(

1

):

138

-

139

.

52.

Dorbala

S

,

Vangala

D

,

Semer

J

, et al.

Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography

.

Eur J Nucl Med Mol Imaging

.

2014

;

41

(

9

):

1652

-

1662

.

53.

Manwani

R

,

Page

J

,

Lane

T

, et al.

A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement

.

Amyloid

.

2018

;

25

(

4

):

247

-

252

.

54.

Baratto

L

,

Park

SY

,

Hatami

N

, et al.

¹⁸F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition

.

EJNMMI Res

.

2018

;

8

(

1

):

66

.

55.

Ehman

EC

,

El-Sady

MS

,

Kijewski

MF

, et al.

Early detection of multiorgan light-chain amyloidosis by whole-body ¹⁸F-florbetapir PET/CT

.

J Nucl Med

.

2019

;

60

(

9

):

1234

-

1239

.

56.

Genovesi

D

,

Vergaro

G

,

Giorgetti

A

, et al.

¹⁸F-florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions

.

JACC Cardiovasc Imaging

.

2021

;

14

(

1

):

246

-

255

.

57.

Cuddy

SAM

,

Bravo

PE

,

Falk

RH

, et al.

Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?

.

JACC Cardiovasc Imaging

.

2020

;

13

(

6

):

1325

-

1336

.

58.

Clerc

OF

,

Datar

Y

,

Cuddy

SAM

, et al.

Prognostic value of left ventricular 18F-florbetapir uptake in systemic light-chain amyloidosis

.

JACC Cardiovasc Imaging

.

2024

;

17

(

8

):

911

-

922

.

59.

Kim

YJ

,

Ha

S

,

Kim

YI

.

Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis

.

J Nucl Cardiol

.

2020

;

27

(

1

):

123

-

132

.

60.

Wall

JS

,

Martin

EB

,

Richey

T

, et al.

Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis

.

Molecules

.

2015

;

20

(

5

):

7657

-

7682

.

61.

Wall

JS

,

Martin

EB

,

Endsley

A

, et al.

First in human evaluation and dosimetry calculations for peptide ¹²⁴I-p5+14-a novel radiotracer for the detection of systemic amyloidosis using PET/CT imaging

.

Mol Imaging Biol

.

2022

;

24

(

3

):

479

-

488

.

62.

Wall

JS

,

Martin

EB

,

Lands

R

, et al.

Cardiac amyloid detection by PET/CT imaging of iodine ¹²⁴I evuzamitide (¹²⁴I-p5+14): a phase 1/2 study

.

JACC Cardiovasc Imaging

.

2023

;

16

(

11

):

1433

-

1448

.